INDP Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of --. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat CEL-SCI Corp.'s return on equity of -266.61%.

Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 392.61%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that CEL-SCI Corp. has higher upside potential than Indaptus Therapeutics, Inc., analysts believe CEL-SCI Corp. is more attractive than Indaptus Therapeutics, Inc..

Indaptus Therapeutics, Inc. has a beta of 1.000, which suggesting that the stock is 0.0099999999999989% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Indaptus Therapeutics, Inc.'s net income of -$3M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of -953.4%. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 392.61%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that IGC Pharma, Inc. has higher upside potential than Indaptus Therapeutics, Inc., analysts believe IGC Pharma, Inc. is more attractive than Indaptus Therapeutics, Inc..

Indaptus Therapeutics, Inc. has a beta of 1.000, which suggesting that the stock is 0.0099999999999989% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Indaptus Therapeutics, Inc.'s net income of -$3M is lower than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of -255.85%. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 392.61%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Indaptus Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Indaptus Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Indaptus Therapeutics, Inc. has a beta of 1.000, which suggesting that the stock is 0.0099999999999989% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Indaptus Therapeutics, Inc.'s net income of -$3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -- compared to Indaptus Therapeutics, Inc.'s net margin of 13.19%. Indaptus Therapeutics, Inc.'s return on equity of -537.86% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Indaptus Therapeutics, Inc. has a consensus price target of $10.00, signalling upside risk potential of 392.61%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Indaptus Therapeutics, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Indaptus Therapeutics, Inc..

Indaptus Therapeutics, Inc. has a beta of 1.000, which suggesting that the stock is 0.0099999999999989% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Indaptus Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Indaptus Therapeutics, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Indaptus Therapeutics, Inc. quarterly revenues are --, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Indaptus Therapeutics, Inc.'s net income of -$3M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Indaptus Therapeutics, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Indaptus Therapeutics, Inc. is -- versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.